87S Stock Overview
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Roivant Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.15 |
| 52 Week High | US$12.30 |
| 52 Week Low | US$7.55 |
| Beta | 1.25 |
| 11 Month Change | 0.89% |
| 3 Month Change | 5.27% |
| 1 Year Change | -10.18% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 85.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 87S | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.8% | -0.7% | 1.1% |
| 1Y | -10.2% | -17.2% | 10.7% |
Return vs Industry: 87S exceeded the German Biotechs industry which returned -16.1% over the past year.
Return vs Market: 87S underperformed the German Market which returned 7.6% over the past year.
Price Volatility
| 87S volatility | |
|---|---|
| 87S Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 87S has not had significant price volatility in the past 3 months.
Volatility Over Time: 87S's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 908 | Matt Gline | roivant.com |
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases.
Roivant Sciences Ltd. Fundamentals Summary
| 87S fundamental statistics | |
|---|---|
| Market cap | €7.87b |
| Earnings (TTM) | €4.24b |
| Revenue (TTM) | €141.65m |
1.8x
P/E Ratio54.6x
P/S RatioIs 87S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 87S income statement (TTM) | |
|---|---|
| Revenue | US$158.30m |
| Cost of Revenue | US$523.34m |
| Gross Profit | -US$365.03m |
| Other Expenses | -US$5.10b |
| Earnings | US$4.74b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.40 |
| Gross Margin | -230.59% |
| Net Profit Margin | 2,991.76% |
| Debt/Equity Ratio | 5.5% |
How did 87S perform over the long term?
See historical performance and comparison